Qrxpharma Ltd (QRXPF) 0.0236 $QRXPF
QRxPharma Provides Feedback On End-of-Review Meeting With The FDA On Moxduo®
PR Newswire - Fri Jul 11, 8:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) today provided feedback on its 9 July End-of-Review (EOR) meeting with the United States Food and Drug Administration (FDA). The meeting was held to discuss the feasibility and requirements for approving Moxduo, an immediate release Dual Opioid®, for the treatment of moderate to severe acute pain.
QRxPharma Announces Board Resignations
PR Newswire - Wed Jul 09, 8:02AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that Chairman, Dr. Peter Farrell and Director, Dr. Gary Pace have resigned from the QRxPharma board effective at 9:50am (AEST) 9 July 2014 prior to commencement of the General Meeting (GM) requisitioned by shareholders associated with Langley Walker. It is expected that Bruce Hancox and Dr. Richard Treagus will be appointed as directors pursuant to resolutions in the requisitioned notice of meeting, with those appointments taking effect from the close of the meeting.
Dystonia - Pipeline Review, H1 2014
M2 - Thu Jun 26, 3:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mgqh87/dystonia) has announced the addition of the "Dystonia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dystonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dystonia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Dystonia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dystonia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Dystonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - Addex Therapeutics - Advicenne Pharma SA - EpiVax, Inc. - Ipsen S.A. - QRxPharma Limited For more information visit http://www.researchandmarkets.com/research/mgqh87/dystonia
FDA Sets 22 April 2014 For Moxduo® Advisory Committee Meeting
PR Newswire - Mon Mar 24, 7:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the United States Food and Drug Administration (FDA) has set 22 April 2014 as the date of the Advisory Committee meeting to consider the Company's resubmitted Moxduo New Drug Application (NDA).
Century21.com Is The No. 1 Most Visited Real Estate Franchise Website
PR Newswire - Thu Jan 16, 8:08AM CST
Century 21 Real Estate LLC, the franchisor of the world's largest residential real estate sales organization, announced today that its website - century21.com - has become the No. 1 "most visited" real estate franchise website. According to comScore, Inc., a global leader in digital measurement and analytics, century21.com attracted more unique visitors than any other real estate franchise brand site in every month of 2013. In fact, century21.com holds a commanding lead in the number of unique website visitors in 2013 with 25.3 million for the entire year, which was approximately 10 million unique visitors higher than the next-closest national franchise brand. In a year where the industry average for all real estate sites was a 1% gain in total unique website visitors, CENTURY 21 posted a 49% year-over-year increase.
Global Moderate Pain Pipeline Review Report - H2 2013
M2 - Fri Dec 20, 8:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/xlmgdg/moderate_pain) has announced the addition of the "Moderate Pain - Pipeline Review, H2 2013" report to their offering. 'Moderate Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Moderate Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Moderate Pain. Scope - A snapshot of the global therapeutic scenario for Moderate Pain. - A review of the Moderate Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Moderate Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Moderate Pain Therapeutics Development - Nektar Therapeutics - Esteve Group - Pain Therapeutics, Inc. - Pfizer Inc. - Menarini Group - Acura Pharmaceuticals, Inc. - Elite Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Trevena, Inc. - QRxPharma Limited - KemPharm, Inc. - TheraQuest Biosciences, LLC Drug Profiles - PTI-202 - (oxycodone naltrexone) - oxycodone ER - PTI-721 - (morphine oxycodone) - NKTR-194 - levorphanol tartrate ER - buprenorphine hydrochloride ER - (dexketoprofen trometamol tramadol hydrochloride) - hydromorphone IR - E-58425 - HS-731 - (promethazine hydrocodone acetaminophen) - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - TRV-734 For more information visit http://www.researchandmarkets.com/research/xl...erate_pain
QRxPharma Announces MOXDUO® License With Aspen
PR Newswire - Wed Sep 11, 8:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution of a licensing agreement with Aspen Pharma Pty Ltd, one of the Australian subsidiaries of Aspen Pharmacare Holdings Limited (JSE: APN), for the commercialisation rights to immediate release MOXDUO in Australia, New Zealand and Oceania. The agreement also provides an option to license the commercialisation rights to immediate release MOXDUO in South Africa. Aspen Pharmacare Holdings Limited is a South African multinational pharmaceutical company supplying branded and generic products in more than 150 countries. One in five prescriptions written in Australia is for an Aspen Group ("Aspen"
distributed product and its Australian business contributes revenues of nearly A$1 billion per annum to Aspen.
Osteoarthritis Pain - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8frj9r/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis Pain. - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genzyme Corporation Johnson & Johnson Allergan, Inc. Amgen Inc. Sanofi-Aventis Eli Lilly and Company BioDelivery Sciences International, Inc. Pfizer Inc. Purdue Pharma L.P. Teva Pharmaceutical Industries Limited Menarini Group BioChemics, Inc. Addex Pharmaceuticals Elite Pharmaceuticals, Inc. POZEN Inc. Array BioPharma Inc. Futura Medical plc. Transition Therapeutics Inc. Palau Pharma S.A Neurotune AG QRxPharma Limited and much more... For more information visit http://www.researchandmarkets.com/research/8f...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
FDA Schedules Review Meeting With QRxPharma Regarding MOXDUO® NDA
PR Newswire - Fri Sep 06, 8:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the United States Food and Drug Administration (FDA) has scheduled a meeting on 3 October to discuss the Company's MOXDUO New Drug Application (NDA) for the treatment of moderate to severe acute pain. The meeting was granted by the FDA after issuance of a Complete Response Letter (CRL) last month, and will focus on outstanding issues that need to be addressed in the revised NDA and data validation documentation.
Acute Pain - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Acute Pain
M2 - Thu Sep 05, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3cmj8z/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Acute Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Pain, complete with latest updates, and special features on late-stage and discontinued projects. Acute Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Acute Pain. - A review of the Acute Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AcelRx Pharmaceuticals, Inc. - Anavex Life Sciences Corp. - AngioChem Inc. - Array BioPharma Inc. - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - CombinatoRx, Incorporated - Cytogel Pharma, LLC - Encore Therapeutics Inc. - Esteve Group - Grunenthal GmbH - Intas Pharmaceuticals Ltd. - Iroko Pharmaceuticals, LLC - Madeira Therapeutics - Menarini Group - Nektar Therapeutics - NeuroTherapeutics Pharma Inc. - Nuvo Research Inc. - Orexo AB - Pacira Pharmaceuticals, Inc. - Pfizer Inc. - QRxPharma Limited - RaQualia Pharma Inc. - Sigma-Tau S.p.A. - Trevena, Inc. For more information visit http://www.researchandmarkets.com/research/3cmj8z/acute_pain About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Dystonia - Pipeline Review, H2 2013 Report Features Players such as Addex Pharmaceuticals and QRxPharma Limited
M2 - Thu Sep 05, 9:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vr9rld/dystonia) has announced the addition of the "Dystonia - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Dystonia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dystonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dystonia. Dystonia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Dystonia. - A review of the Dystonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dystonia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Addex Pharmaceuticals - QRxPharma Limited For more information visit http://www.researchandmarkets.com/research/vr9rld/dystonia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Duchenne Muscular Dystrophy - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dxghnf/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H2 2013" report to their offering. 'Duchenne Muscular Dystrophy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Duchenne Muscular Dystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy. Scope - A snapshot of the global therapeutic scenario for Duchenne Muscular Dystrophy. - A review of the Duchenne Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Duchenne Muscular Dystrophy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genzyme Corporation Johnson & Johnson Allergan, Inc. Amgen Inc. Sanofi-Aventis Eli Lilly and Company BioDelivery Sciences International, Inc. Pfizer Inc. Purdue Pharma L.P. Teva Pharmaceutical Industries Limited Menarini Group BioChemics, Inc. Addex Pharmaceuticals Elite Pharmaceuticals, Inc. POZEN Inc. Array BioPharma Inc. Futura Medical plc. Transition Therapeutics Inc. Palau Pharma S.A Neurotune AG QRxPharma Limited Iroko Pharmaceuticals, LLC and many more.... For more information visit http://www.researchandmarkets.com/research/dx...e_muscular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
QRxPharma Receives Complete Response Letter From FDA Regarding MOXDUO® NDA
PR Newswire - Tue Aug 27, 6:24PM CDT
Additional time required to prepare and review respiratory data from Study 022
QRxPharma Announces Collaboration With Aesica
PR Newswire - Mon Jul 22, 6:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution of a Collaboration Agreement with Aesica Formulation Development Limited, a subsidiary of Aesica Pharmaceuticals Limited, for the world-wide promotion of QRxPharma's proprietary Stealth Beadlets® abuse deterrence technology. Aesica supplies pharmaceutical contract development and manufacturing services globally and operates six manufacturing sites across the UK, Germany and Italy. Aesica offers controlled drug services across the supply chain for which abuse or diversion may occur and is actively building relationships for supplying controlled drug Active Pharmaceutical Ingredients (APIs) and finished dose products to market.
QRxPharma Updates MOXDUO® NDA Review
PR Newswire - Wed Jun 26, 8:14AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the planned 17 July 2013 US Food and Drug Administration (FDA) Advisory Committee meeting to consider the MOXDUO combination opioid analgesic New Drug Application (NDA) will be delayed in order to allow the Company and the FDA time to fully consider results of recent findings for Study 022. The NDA was re-filed in late February 2013, with the original Advisory Committee meeting scheduled for 17 July 2013 and the Prescription Drug User Fee Act (PDUFA) date was 26 August 2013.
Back Pain - Global Pipeline Review Report, H1 2013 Edition
M2 - Wed Jun 19, 10:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v9vbt8/back_pain) has announced the addition of the "Back Pain - Pipeline Review, H1 2013" report to their offering. 'Back Pain - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Back Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Back Pain. Scope - A snapshot of the global therapeutic scenario for Back Pain. - A review of the Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Back Pain pipeli
QRxPharma Granted US Patent On Hybrid Opioids
PR Newswire - Wed Jun 12, 8:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the United States Patent and Trademark Office (USPTO) issued the Company U.S. Patent #8,461,171 ("'171 patent" titled "Hybrid Opioid Compounds and Compositions," which expires in 2031. This patent covers a hybrid morphine-oxycodone molecule where these two different opioids are chemically linked. The '171 patent covers the development of new chemical entities that have the potential to provide better pain relief and fewer side effects than their individual components. The Company has related patents pending both internationally and in the United States.
Global Hemorrhage Pipeline Review Report, H1 2013 Edition
M2 - Fri Jun 07, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hr27qt/hemorrhage) has announced the addition of the "Hemorrhage - Pipeline Review, H1 2013" report to their offering. 'Hemorrhage - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemorrhage, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemorrhage. Scope - A snapshot of the global therapeutic scenario for Hemorrhage. - A review of the Hemorrhage products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemorrhag
Low Back Pain - Pipeline Review Report, H1 2013 Edition
M2 - Wed Jun 05, 10:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dv4v9h/low_back_pain) has announced the addition of the "Low Back Pain - Pipeline Review, H1 2013" report to their offering. 'Low Back Pain - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Low Back Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Low Back Pain. Scope - A snapshot of the global therapeutic scenario for Low Back Pain. - A review of the Low Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Cove
Moderate Pain - Pipeline Review Report, H1 2013 Edition
M2 - Tue Jun 04, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f5svm4/moderate_pain) has announced the addition of the "Moderate Pain - Pipeline Review, H1 2013" report to their offering. 'Moderate Pain - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Moderate Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Moderate Pain. Scope - A snapshot of the global therapeutic scenario for Moderate Pain. - A review of the Moderate Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Cove
QRxPharma Provides Feedback On End-of-Review Meeting With The FDA On Moxduo®
PR Newswire - Fri Jul 11, 8:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) today provided feedback on its 9 July End-of-Review (EOR) meeting with the United States Food and Drug Administration (FDA). The meeting was held to discuss the feasibility and requirements for approving Moxduo, an immediate release Dual Opioid®, for the treatment of moderate to severe acute pain.
QRxPharma Announces Board Resignations
PR Newswire - Wed Jul 09, 8:02AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that Chairman, Dr. Peter Farrell and Director, Dr. Gary Pace have resigned from the QRxPharma board effective at 9:50am (AEST) 9 July 2014 prior to commencement of the General Meeting (GM) requisitioned by shareholders associated with Langley Walker. It is expected that Bruce Hancox and Dr. Richard Treagus will be appointed as directors pursuant to resolutions in the requisitioned notice of meeting, with those appointments taking effect from the close of the meeting.
Dystonia - Pipeline Review, H1 2014
M2 - Thu Jun 26, 3:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mgqh87/dystonia) has announced the addition of the "Dystonia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dystonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dystonia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Dystonia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dystonia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Dystonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - Addex Therapeutics - Advicenne Pharma SA - EpiVax, Inc. - Ipsen S.A. - QRxPharma Limited For more information visit http://www.researchandmarkets.com/research/mgqh87/dystonia
FDA Sets 22 April 2014 For Moxduo® Advisory Committee Meeting
PR Newswire - Mon Mar 24, 7:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the United States Food and Drug Administration (FDA) has set 22 April 2014 as the date of the Advisory Committee meeting to consider the Company's resubmitted Moxduo New Drug Application (NDA).
Century21.com Is The No. 1 Most Visited Real Estate Franchise Website
PR Newswire - Thu Jan 16, 8:08AM CST
Century 21 Real Estate LLC, the franchisor of the world's largest residential real estate sales organization, announced today that its website - century21.com - has become the No. 1 "most visited" real estate franchise website. According to comScore, Inc., a global leader in digital measurement and analytics, century21.com attracted more unique visitors than any other real estate franchise brand site in every month of 2013. In fact, century21.com holds a commanding lead in the number of unique website visitors in 2013 with 25.3 million for the entire year, which was approximately 10 million unique visitors higher than the next-closest national franchise brand. In a year where the industry average for all real estate sites was a 1% gain in total unique website visitors, CENTURY 21 posted a 49% year-over-year increase.
Global Moderate Pain Pipeline Review Report - H2 2013
M2 - Fri Dec 20, 8:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/xlmgdg/moderate_pain) has announced the addition of the "Moderate Pain - Pipeline Review, H2 2013" report to their offering. 'Moderate Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Moderate Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Moderate Pain. Scope - A snapshot of the global therapeutic scenario for Moderate Pain. - A review of the Moderate Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Moderate Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Moderate Pain Therapeutics Development - Nektar Therapeutics - Esteve Group - Pain Therapeutics, Inc. - Pfizer Inc. - Menarini Group - Acura Pharmaceuticals, Inc. - Elite Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Trevena, Inc. - QRxPharma Limited - KemPharm, Inc. - TheraQuest Biosciences, LLC Drug Profiles - PTI-202 - (oxycodone naltrexone) - oxycodone ER - PTI-721 - (morphine oxycodone) - NKTR-194 - levorphanol tartrate ER - buprenorphine hydrochloride ER - (dexketoprofen trometamol tramadol hydrochloride) - hydromorphone IR - E-58425 - HS-731 - (promethazine hydrocodone acetaminophen) - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - TRV-734 For more information visit http://www.researchandmarkets.com/research/xl...erate_pain
QRxPharma Announces MOXDUO® License With Aspen
PR Newswire - Wed Sep 11, 8:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution of a licensing agreement with Aspen Pharma Pty Ltd, one of the Australian subsidiaries of Aspen Pharmacare Holdings Limited (JSE: APN), for the commercialisation rights to immediate release MOXDUO in Australia, New Zealand and Oceania. The agreement also provides an option to license the commercialisation rights to immediate release MOXDUO in South Africa. Aspen Pharmacare Holdings Limited is a South African multinational pharmaceutical company supplying branded and generic products in more than 150 countries. One in five prescriptions written in Australia is for an Aspen Group ("Aspen"
distributed product and its Australian business contributes revenues of nearly A$1 billion per annum to Aspen. Osteoarthritis Pain - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8frj9r/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis Pain. - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genzyme Corporation Johnson & Johnson Allergan, Inc. Amgen Inc. Sanofi-Aventis Eli Lilly and Company BioDelivery Sciences International, Inc. Pfizer Inc. Purdue Pharma L.P. Teva Pharmaceutical Industries Limited Menarini Group BioChemics, Inc. Addex Pharmaceuticals Elite Pharmaceuticals, Inc. POZEN Inc. Array BioPharma Inc. Futura Medical plc. Transition Therapeutics Inc. Palau Pharma S.A Neurotune AG QRxPharma Limited and much more... For more information visit http://www.researchandmarkets.com/research/8f...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
FDA Schedules Review Meeting With QRxPharma Regarding MOXDUO® NDA
PR Newswire - Fri Sep 06, 8:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the United States Food and Drug Administration (FDA) has scheduled a meeting on 3 October to discuss the Company's MOXDUO New Drug Application (NDA) for the treatment of moderate to severe acute pain. The meeting was granted by the FDA after issuance of a Complete Response Letter (CRL) last month, and will focus on outstanding issues that need to be addressed in the revised NDA and data validation documentation.
Acute Pain - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Acute Pain
M2 - Thu Sep 05, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3cmj8z/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Acute Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Pain, complete with latest updates, and special features on late-stage and discontinued projects. Acute Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Acute Pain. - A review of the Acute Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AcelRx Pharmaceuticals, Inc. - Anavex Life Sciences Corp. - AngioChem Inc. - Array BioPharma Inc. - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - CombinatoRx, Incorporated - Cytogel Pharma, LLC - Encore Therapeutics Inc. - Esteve Group - Grunenthal GmbH - Intas Pharmaceuticals Ltd. - Iroko Pharmaceuticals, LLC - Madeira Therapeutics - Menarini Group - Nektar Therapeutics - NeuroTherapeutics Pharma Inc. - Nuvo Research Inc. - Orexo AB - Pacira Pharmaceuticals, Inc. - Pfizer Inc. - QRxPharma Limited - RaQualia Pharma Inc. - Sigma-Tau S.p.A. - Trevena, Inc. For more information visit http://www.researchandmarkets.com/research/3cmj8z/acute_pain About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Dystonia - Pipeline Review, H2 2013 Report Features Players such as Addex Pharmaceuticals and QRxPharma Limited
M2 - Thu Sep 05, 9:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vr9rld/dystonia) has announced the addition of the "Dystonia - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Dystonia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dystonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dystonia. Dystonia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Dystonia. - A review of the Dystonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dystonia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Addex Pharmaceuticals - QRxPharma Limited For more information visit http://www.researchandmarkets.com/research/vr9rld/dystonia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Duchenne Muscular Dystrophy - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dxghnf/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H2 2013" report to their offering. 'Duchenne Muscular Dystrophy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Duchenne Muscular Dystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy. Scope - A snapshot of the global therapeutic scenario for Duchenne Muscular Dystrophy. - A review of the Duchenne Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Duchenne Muscular Dystrophy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genzyme Corporation Johnson & Johnson Allergan, Inc. Amgen Inc. Sanofi-Aventis Eli Lilly and Company BioDelivery Sciences International, Inc. Pfizer Inc. Purdue Pharma L.P. Teva Pharmaceutical Industries Limited Menarini Group BioChemics, Inc. Addex Pharmaceuticals Elite Pharmaceuticals, Inc. POZEN Inc. Array BioPharma Inc. Futura Medical plc. Transition Therapeutics Inc. Palau Pharma S.A Neurotune AG QRxPharma Limited Iroko Pharmaceuticals, LLC and many more.... For more information visit http://www.researchandmarkets.com/research/dx...e_muscular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
QRxPharma Receives Complete Response Letter From FDA Regarding MOXDUO® NDA
PR Newswire - Tue Aug 27, 6:24PM CDT
Additional time required to prepare and review respiratory data from Study 022
QRxPharma Announces Collaboration With Aesica
PR Newswire - Mon Jul 22, 6:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution of a Collaboration Agreement with Aesica Formulation Development Limited, a subsidiary of Aesica Pharmaceuticals Limited, for the world-wide promotion of QRxPharma's proprietary Stealth Beadlets® abuse deterrence technology. Aesica supplies pharmaceutical contract development and manufacturing services globally and operates six manufacturing sites across the UK, Germany and Italy. Aesica offers controlled drug services across the supply chain for which abuse or diversion may occur and is actively building relationships for supplying controlled drug Active Pharmaceutical Ingredients (APIs) and finished dose products to market.
QRxPharma Updates MOXDUO® NDA Review
PR Newswire - Wed Jun 26, 8:14AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the planned 17 July 2013 US Food and Drug Administration (FDA) Advisory Committee meeting to consider the MOXDUO combination opioid analgesic New Drug Application (NDA) will be delayed in order to allow the Company and the FDA time to fully consider results of recent findings for Study 022. The NDA was re-filed in late February 2013, with the original Advisory Committee meeting scheduled for 17 July 2013 and the Prescription Drug User Fee Act (PDUFA) date was 26 August 2013.
Back Pain - Global Pipeline Review Report, H1 2013 Edition
M2 - Wed Jun 19, 10:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v9vbt8/back_pain) has announced the addition of the "Back Pain - Pipeline Review, H1 2013" report to their offering. 'Back Pain - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Back Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Back Pain. Scope - A snapshot of the global therapeutic scenario for Back Pain. - A review of the Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Back Pain pipeli
QRxPharma Granted US Patent On Hybrid Opioids
PR Newswire - Wed Jun 12, 8:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the United States Patent and Trademark Office (USPTO) issued the Company U.S. Patent #8,461,171 ("'171 patent"
titled "Hybrid Opioid Compounds and Compositions," which expires in 2031. This patent covers a hybrid morphine-oxycodone molecule where these two different opioids are chemically linked. The '171 patent covers the development of new chemical entities that have the potential to provide better pain relief and fewer side effects than their individual components. The Company has related patents pending both internationally and in the United States. Global Hemorrhage Pipeline Review Report, H1 2013 Edition
M2 - Fri Jun 07, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hr27qt/hemorrhage) has announced the addition of the "Hemorrhage - Pipeline Review, H1 2013" report to their offering. 'Hemorrhage - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemorrhage, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemorrhage. Scope - A snapshot of the global therapeutic scenario for Hemorrhage. - A review of the Hemorrhage products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemorrhag
Low Back Pain - Pipeline Review Report, H1 2013 Edition
M2 - Wed Jun 05, 10:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dv4v9h/low_back_pain) has announced the addition of the "Low Back Pain - Pipeline Review, H1 2013" report to their offering. 'Low Back Pain - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Low Back Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Low Back Pain. Scope - A snapshot of the global therapeutic scenario for Low Back Pain. - A review of the Low Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Cove
Moderate Pain - Pipeline Review Report, H1 2013 Edition
M2 - Tue Jun 04, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f5svm4/moderate_pain) has announced the addition of the "Moderate Pain - Pipeline Review, H1 2013" report to their offering. 'Moderate Pain - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Moderate Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Moderate Pain. Scope - A snapshot of the global therapeutic scenario for Moderate Pain. - A review of the Moderate Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Cove
